

Please Direct All Correspondence to Customer Number **20995**

**TRANSMITTAL LETTER**  
**INFORMATION DISCLOSURE STATEMENT**

Applicant : Girard et al.  
App. No : 10/601,072  
Filed : June 19, 2003  
For : CHEMOKINE-BINDING PROTEIN AND  
METHOD OF USE  
Examiner : Unknown  
Art Unit : 1641

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

December 16, 2004

(Date)

  
Jerry L. Hefner, Reg. No. 53,009


**Mail Stop Amendment**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) Supplemental Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
  - (X) Listing 7 references.
  - (X) Enclosing 7 references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

  
Jerry L. Hefner  
Registration No. 53,009  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Applicant : Girard et al.  
App. No : 10/601,072  
Filed : June 19, 2003  
For : CHEMOKINE-BINDING PROTEIN  
AND METHODS OF USE  
Examiner : Unknown  
Art Unit : 1641

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a Supplemental Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing 7 copies of foreign patent references and/or non-patent literature that are also enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits.

CERTIFICATION UNDER 37 C.F.R. § 1.97(e)(1)

I hereby certify that each item of information contained in this Statement was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.


Appl. No. : 10/601,072  
Filed : June 19, 2003

Docket No. BIOBANK.009CP1  
Customer No. 20,995

Thus, no fee is required as set forth in 37 C.F.R. § 1.97(c).

Respectfully submitted,  
KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: December 16, 2004

By:   
Jerry L. Hefner  
Registration No. 53,009  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

IDS  
S:\DOCS\VLH\VLH-3067.DOC  
120904

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No. 10/601,072  
 Filing Date June 19, 2003  
 First Named Inventor Girard et al.  
 Art Unit Unknown  
 Examiner 1641  
 Attorney Docket No. BIOBANK.009CP1

(Multiple sheets used when necessary)

SHEET 1 OF 1

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
	1	WO 03/051917 A2	06.23.2003	Endocube SAS		
	2	WO 2004/055050 A2	07.01.2004	Clouaire, Thomas		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	3	Database accession no. AAM79266. Human proteins SEQ ID 1928. (2001)	
	4	International Search Report from co-pending PCT/IB2004/002467 dated October 21, 2004	
	5	ROUSSIGNE, Trends in Biochemical Sciences, Vol. 28, No. 2, Feb. 2003, Elsevier Publication, Cambridge, EN. <i>The THAP domain: a novel protein motif with similarity to the DNA-binding domain of P element transposase.</i>	
	6	ROUSSIGNE, Oncogene, Vol. 22, No. 16, Apr. 24, 2003. <i>THAP1 is a nuclear proapoptotic factor that links prostate-apoptosis-response-4 (Par-4) to PML nuclear bodies.</i>	
	7	Written Opinion from co-pending PCT/IB2004/002467 dated October 21, 2004	

S:\DOCS\JLHJLH-3057.DOC  
120804

Examiner Signature

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.